CME 2.00 credits
Marc J. Semigran, MD (Chair)
Martha Grogan, MD
Frederick L. Ruberg, MD
James R. Stone, MD, PhD
Angela Dispenzieri, MD
Click the "Start Activity" button to indicate you have reviewed the CME information listed below for this activity.
Credits: None available.
CARDIAC AMYLOIDOSIS - A Multidisciplinary Approach to Understanding, Diagnosis and Treatment
An online educational activity based on a CME Satellite Symposium presented at the 20h Annual Meeting of the Heart Failure Society of America in Orlando, FL.
This activity is intended for cardiovascular specialists, cardiovascular nurses and nurse practitioners, pharmacists, scientist and other healthcare professionals caring for patients with heart failure.
Date of Release: December 1, 2016
Program End Date: November 30, 2017
Upon completion of this activity, participants will be able to:
Physician: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Heart Failure Society of America designates this online activity for a maximum of 2.00 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Course Content - CARDIAC AMYLOIDOSIS - A Multidisciplinary Approach to Understanding, Diagnosis and Treatment
Welcome and Introduction of Speakers
Marc J. Semigran
Epidemiology and Prognosis
Marc J. Semigran
Pathophysiology of Amyloidosis, Including Subtypes
Initial Diagnostic Workup
Frederick L. Ruberg
What Next? Role of Cardiac Biopsy
James R. Stone
Genotype: Who Should Be Genotyped and Why?
Frederick L. Ruberg, Angela Dispenzieri
Q&A and Panel Discussion
As a provider accredited by ACCME, HFSA ensures balance, independence, objectivity and scientific rigor in its educational activities. Course Directors, planning committee members, and speakers are required to disclose all relevant financial relationships. Faculty will also disclose off‐label or investigational uses of pharmaceuticals or devices discussed in their presentations. All potential conflicts have been resolved in accordance with ACCME guidelines for commercial support and content validation.
Angela Dispenzieri, MD indicated no relevant financial relationships.
Martha Grogan, MD disclosed the following relevant financial releationships: Research Grants: Pfizer, Alnylam Speaking/Honoraria: Prothena Consultant/Advisory: Pfizer, Prothena
Frederick L. Ruberg, MD indicated no relevant financial relationships.
Marc J. Semigran, MD indicated the following relationships: Research Grants: St. Jude Medical, CVRx, Novartis Consultant/Advisory: Broadview, Amgen
James R. Stone, MD, PhD indicated the following relationships:
HFSA Planner / Reviewer Disclosures:
John Burnett, Jr., MD, has disclosed no relevant financial relationships.
Mona Fiuzat, PharmD, has disclosed no relevant financial relationships.
Gregg Fonarow, MD, has disclosed the following relevant financial relationships: Research Grants: National Institutes of Health (NIH). Consultant/Advisory Board: Amgen Inc.; Janssen Pharmaceuticals, Inc.; Medtronic; and Novartis Pharmaceuticals Corporation; St. Jude; and ZS Pharma
Kenneth Margulies, MD, has disclosed the following relevant financial relationships: Research Grants: CardioCell, LLC; Merk; Sharp and Dohme; and St. Lukes Hospital (Kansas City) Consultant/Advisory Board: GlaxoSmithKline; Merk; Janssen Pharmaceuticals, Inc.; and Sharp and Dohme.
Debra Moser, DNSc, RN, has disclosed no relevant financial relationships.
Marc Semigran, MD, has disclosed the following relevant financial relationships: Research Grants: CVRx. Inc.; St. Jude Medical; and Novartis Pharmaceuticals Corporation. Consultant/Advisory Board: Amgen Inc.; and Broadview.
David Whellan, MD, has disclosed no relevant financial relationships.
Jaime Abreu, MBA, has disclosed no relevant financial relationships.
Dawn Saterdalen, RN, MBA, has disclosed no relevant financial relationships.
Denise Broderick, BSc, has disclosed no relevant financial relationships.
Support for this enduring activity was provided through an independent educational grant from the Amyloidosis Research Consortium (ARC) with support from: Pfizer, Prothena, Alnylam and Ionis Pharmaceuticals
Method of Participation and CME Certificate
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
To receive CME credit for this product, the participant must:
After successfully completing the post-test and evaluation, your CME certificate will be generated and immediately available for print.
Medium or Combination of Media Used
This enduring activity is available in these format offerings:
For support related to this site, please contact: email@example.com or Toll Free: 877‐796‐1325
The website is provided by the Heart Failure Society of America (HFSA). HFSA only obtains personal information that you provide through your participation in this educational activity. Information is collected and retained solely for the purpose of identifying those who have participate and completed this activity. Your personal information will not be sold to any other entity.